← Leaderboards
Erik Ian Tucker
Aronora, Inc.
$22,365,229
Attributed
$39,111,465
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$39,111,465 · 13
By mechanism
R44$38,188,786 · 10
R43$922,679 · 3
Top collaborators
- Christina U Lorentz13 shared
- Norah Verbout12 shared
- Andras Gruber10 shared
- Michael Wallisch3 shared
- Philberta Yuenhui Leung1 shared
Most similar at Aronora, Inc.
Same institution · by research overlap
- Christina U Lorentz$5,989,807
- Norah Verbout$5,329,869
- Michael Wallisch$1,130,711
- Philberta Yuenhui Leung$157,833
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsHemorrhageDosePrimatesBlood CoagulationSafetyMedicalToxic EffectProduct DevelopmentAnticoagulantsHemostatic FunctionPreventSmall Business Innovation Research GrantAnticoagulationDrug CandidateThrombusThrombinHemostatic AgentsLeadThrombosisLifeCoagulation ProcessAdverse EffectsClinical Trials
Grant awards (47)
Contact Pathway Inhibitor to Prevent Vascular Access Failure$1,331,056
R44 · FY2025 · HL
Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis$1,069,527
R44 · FY2025 · HL
Contact Pathway Inhibitor to Prevent Vascular Access Failure$1,480,856
R44 · FY2024 · HL
Thrombopoietin Targeting in Myeloproliferative Neoplasms$669,111
R44 · FY2024 · HL
Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis$493,999
R44 · FY2024 · HL
Antithrombotic Protein C Activator for Hemodialysis$999,415
R44 · FY2023 · HL · contact PI
Contact Pathway Inhibitor to Prevent Vascular Access Failure$998,549
R44 · FY2023 · HL
Thrombopoietin Targeting in Myeloproliferative Neoplasms$700,302
R44 · FY2023 · HL
Antithrombotic Protein C Activator for Hemodialysis$999,415
R44 · FY2022 · HL · contact PI
Factor XII Inhibitor for Surface Initiated Thrombosis$953,492
R44 · FY2022 · HL · contact PI
Thrombopoietin Targeting in Myeloproliferative Neoplasms$301,788
R44 · FY2022 · HL
Antithrombotic Protein C Activator for Hemodialysis$998,345
R44 · FY2021 · HL · contact PI
Factor XII Inhibitor for Surface Initiated Thrombosis$981,954
R44 · FY2021 · HL · contact PI
Antithrombotic Protein C Activator for Hemodialysis$1,493,466
R44 · FY2020 · HL · contact PI
Factor XII Inhibitor for Surface Initiated Thrombosis$999,930
R44 · FY2020 · HL · contact PI
Factor XI inhibitor for thrombosis$999,525
R44 · FY2019 · HL · contact PI
Therapeutic Protein C Activator for Myocardial Ischemia$998,750
R44 · FY2019 · HL · contact PI
Antithrombotic Protein C Activator for Hemodialysis$994,097
R44 · FY2019 · HL · contact PI
Factor XI inhibitor for thrombosis$999,525
R44 · FY2018 · HL · contact PI
Therapeutic Protein C Activator for Myocardial Ischemia$999,263
R44 · FY2018 · HL · contact PI
HLS- Factor XII Inhibitor for Surface Initiated Thrombosis$963,088
R44 · FY2018 · HL · contact PI
HLS- Factor XII Inhibitor for Surface Initiated Thrombosis$998,771
R44 · FY2017 · HL · contact PI
Therapeutic Protein C Activator for Myocardial Ischemia$998,107
R44 · FY2017 · HL · contact PI
Therapeutic factor XI blockade for sepsis$359,659
R44 · FY2017 · HL · contact PI
Therapeutic factor XI blockade for sepsis$997,083
R44 · FY2016 · HL · contact PI
Therapeutic Thrombin Analogs$872,549
R44 · FY2016 · HL · contact PI
HLS- Factor XII Inhibitor for Surface Initiated Thrombosis$299,563
R44 · FY2016 · HL · contact PI
Therapeutic factor XI blockade for sepsis$999,329
R44 · FY2015 · HL · contact PI
Therapeutic Thrombin Analogs$957,597
R44 · FY2015 · HL · contact PI
Therapeutic Protein C Activator for Myocardial Ischemia$945,814
R44 · FY2015 · HL
Therapeutic Protein C Activator for Myocardial Ischemia$5,000
R44 · FY2015 · HL
Factor XI inhibitor for thrombosis$992,182
R44 · FY2014 · HL · contact PI
Therapeutic factor XI blockade for sepsis$983,121
R44 · FY2014 · AI · contact PI
Therapeutic Protein C Activator for Myocardial Ischemia$967,201
R44 · FY2014 · HL
Therapeutic Thrombin Analogs$834,603
R44 · FY2014 · HL · contact PI
Factor XI inhibitor for thrombosis$992,422
R44 · FY2013 · HL · contact PI
Therapeutic factor XI blockade for sepsis$974,608
R44 · FY2013 · AI · contact PI
Therapeutic Protein C Activator for Myocardial Ischemia$260,864
R44 · FY2013 · HL
Therapeutic factor XI blockade for sepsis$1,000,000
R44 · FY2012 · AI · contact PI
Factor XI inhibitor for thrombosis$999,377
R44 · FY2012 · HL · contact PI
Factor XI Inhibition for the Treatment of Ischemic Stroke$315,665
R43 · FY2012 · NS
Therapeutic thrombin analogs$1,373,097
R44 · FY2011 · HL · contact PI
Factor XI inhibitor for thrombosis$309,528
R43 · FY2011 · HL · contact PI
Therapeutic thrombin analogs$99,765
R44 · FY2011 · HL · contact PI
Therapeutic thrombin analogs$398,147
R44 · FY2010 · HL · contact PI
Therapeutic factor XI blockade for sepsis$297,486
R43 · FY2010 · AI · contact PI
Therapeutic thrombin analogs$454,474
R44 · FY2009 · HL · contact PI